With glitazones and sulfonylureas retreating, and first generation incretins now established, it was fascinating to hear how thought leaders are starting to differentiate the new GLP-1s, DPP4s, SGLT2s, and alternative insulin formulations.
Scottsdale, AZ (PRWEB) November 12, 2010
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Diabetes/Obesity,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for treatments in these disease areas.
“In this report, our panel of experts describes the clinical progress of the most interesting therapeutic candidates in the pipeline,” according to Dr. Jeff Berk, MedPredict’s president and lead author of this report. “With glitazones and sulfonylureas retreating, and first generation incretins now established, it was fascinating to hear how thought leaders are starting to differentiate the new GLP-1s, DPP4s, SGLT2s, and alternative insulin formulations.”
MedPredict interviewed N. American and European thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. Drug classes discussed include biguanides (metformin), DPP4 inhibitors, GLP-1 agonists, PPAR, secretagogues, SGLT2, GPR-119, insulins and (briefly) amphetamines.
Some of the questions addressed by this panel include:
- What are the advantages and disadvantages of GLP-1 agonists vs. DPP4 inhibitors?
- What will be the impact of the FDA’s complete response letter to Lilly/Amylin requesting additional Bydureon data uptake of Novo Nordisk’s Victoza?
- What are Victoza’s advantages vs. Lilly/Amylin’s Byetta?
- Is the increased pancreatitis seen with GLP-1’s due to mechanism of action, or related to the disease condition?
- What will be one of the keys to physician acceptance of SGLT2 inhibitors?
- How do panelists distinguish between Merck’s Januvia and BMS/AZ’s Onglyza?
- How will Kombiglyze XR (a once-daily form of saxagliptin just approved by FDA) or Boehringer Ingelheim’s Ondero (linagliptin, expected filing 4Q 2010) impact prescribing in the DPP4 class?
- What is the outlook for MannKind’s inhaled insulin product, Afrezza? Will their Technosphere delivery system overcome the negative impact on lung function that caused Pfizer’s Exubera to be discontinued?
Companies/partnerships discussed in this report: Arena, AstraZeneca/Bristol-Myers Squibb, Boehringer Ingelheim, Generex/Shreya, GlaxoSmithKline, Johnson & Johnson/Depomed, Lilly/Amylin, Lilly, Lilly/Takeda, Lexicon, MannKind, Merck, Novo Nordisk, Oramed, Pfizer/Nektar, Roche/Ipsen, Sanofi-Aventis, Transition Therapeutics, and Vivus.
The full report may be purchased by contacting MedPredict.
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.
For more information contact:
# # #